finanzen.net
18.04.2019 15:28
Bewerten
(0)

Medicinal Genomics announces Cannabis Pan-Genome project, a major advance in genetics for cannabis breeding

DRUCKEN

Pacific Biosciences Sequel II System genetic analysis platform to catalog structural variants—the genetic hotspots—governing cannabis chemotype

BEVERLY, Mass., April 18, 2019 /CNW/ -- Medicinal Genomics Corp. (MGC), a pioneer in using genomics to improve the quality, quantity and safety of cannabis, announced the initiation of a cannabis pan-genome project, a comparative genetic analysis of several different cannabis cultivars to identify genomic structural variations.

Building upon a recently updated reference genome of the Jamaican Lion cultivar, MGC has identified the genetic variations that cause a plant to produce the important cannabinoids of THC, CBD, or a mixture of the two, referred to as chemotypes (I-IV). This information provides a "cookbook" of genetic recipes for different types and cultivars, and is a key to breeding for cannabis yield, potency and a host of other traits.

"The pan-genome focuses on whole genome sequencing and de novo assembly using the Sequel II System by Pacific Biosciences (PacBio) to catalog structural variation inheritance patterns in closely and distantly related cultivars. This family of genomes will form the foundation for cannabis breeding programs across the industry," said Medicinal Genomics Chief Scientific Officer, Kevin McKernan. "The economic value of the genetics that govern cannabinoid expression, seed development, and fiber yield is one of the most promising opportunities of the decade. And now, every breeder and grower can use this tool, retaining complete ownership of the results for their own cultivars."

The project was seeded with a cryptocurrency grant from the Dash DAO in June of 2018. Since then, over 200 Gb of PacBio sequencing has been performed on Jamaican Lion to assemble the genome and build transcriptome and methylation maps across multiple tissue types.

A new standard for cannabis genetics
The completeness of a genome assembly is calibrated in a number known as "N50."  Assemblies with low N50 numbers are like photographs missing thousands of pixels. Leave out enough pixels and the image is incomprehensible. The longer the N50 number, the more information the assembly contains. The latest MGC cannabis assembly has an N50 of 7.6 megabases with a completeness of approximately 97%, establishing a new industry record. This updated reference is the foundational piece to the Pan Cannabis Genome and is accessible to all MGC partners.

Using MGC's assembly of the female Jamaican Lion cultivar as a baseline, genomic DNA from a sibling male plant and multiple offspring were isolated and are being sequenced with the Sequel II System long-read platform to identify structural variations and other types of important genetic variations. This "family" sequencing strategy yields a recombination map and is the basis for creating a pan-genome of cannabis.

"The annotation of structural variations in cannabis will be critical to understanding the genetics of yield, seed production, and other desirable traits," said Timothy Harkins, MGC Senior Advisor. "We continue to build new genetic tools for the entire community by using the Jamaican Lion assembly combined with the methylation and transcriptome maps and now the recombination hotspots. This combination of data and technologies are accelerating our insights, which breeders and growers can now take advantage of. None of it would be possible, however, without the extraordinarily long sequencing read lengths generated by the PacBio platform. This genetic tool wasn't available until they came along, and that has made all the difference."

The program's progress will be presented at a webinar in June, hosted by PacBio, and at the SMRT Leiden meeting in Leiden, Netherlands this May.

About Medicinal Genomics Corporation 
Medicinal Genomics Corporation is a pioneer in advancing the genomics of cannabis to build a stronger scientific foundation for cannabis-based products. The company's unmatched expertise in genetic science helps cultivators, dispensaries and testing laboratories characterize and understand the quality and consistency of cannabis to ensure patients and consumers access to consistently safe, high quality cannabis. To support this work, Medicinal Genomics also produces CannMed, a gathering of cannabis leaders, dedicated to furthering the state of the art in medicinal cannabis, and Kannapedia, the world's most complete public cannabis strain database. For more information, please visit www.medicinalgenomics.com.

MGC media contact:
Ben Amirault
ben.amirault@medicinalgenomics.com 
(978) 430-0888

(PRNewsfoto/Medicinal Genomics)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/medicinal-genomics-announces-cannabis-pan-genome-project-a-major-advance-in-genetics-for-cannabis-breeding-300834647.html

SOURCE Medicinal Genomics

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX schließt klar im Minus -- US-Börsen rot -- Tesla-Aktie nach Analyse unter Druck -- Infineon setzt wohl Chip-Lieferungen an Huawei aus - Unternehmen dementiert -- Wirecard, Deutsche Bank im Fokus

Halbleiterwerte leiden unter Sorge um Huawei-Lieferbeziehungen. HSBC-Analyse setzt Apple-Aktie unter Druck. Bitcoin hält sich nach Kursturbulenzen bei 8.000 US-Dollar. MorphoSys: Zeitplan für erstes eigenes Medikament bleibt unverändert. Pfeiffer Vacuum und Mehrheitsaktionär Busch kooperieren.

Die 5 beliebtesten Top-Rankings

Diese Aktien hat Warren Buffett im Depot
Die Änderungen unter den Top-Positionen
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
In diesen Berufen bekommt man das höchste Gehalt
Mit welchem Beruf kommt man am ehesten an die Spitze?
Städte für Millionäre
Hier fühlen sich die Vermögenden am wohlsten
In diesen Ländern ist Netflix am billigsten
Wo zahlen Abonnenten am wenigsten?
mehr Top Rankings

Umfrage

Die rechtspopulistische FPÖ in Österreich hat für einen Skandal gesorgt. Wie glauben Sie wird sich das auf die Europawahlen auswirken?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Huawei TechnologiesHWEI11
Deutsche Bank AG514000
TeslaA1CX3T
Daimler AG710000
CommerzbankCBK100
Apple Inc.865985
Amazon906866
Infineon AG623100
BayerBAY001
BASFBASF11
NEL ASAA0B733
Deutsche Telekom AG555750
Allianz840400
BMW AG519000